LAUSR

Experts’ summary: This contemporary, cross-sectional investigation of 952 testicular cancer (TC) survivors cured after four cycles of etoposide and cisplatin (EPX4, n = 294) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3, n = 364; BEPX4, n = 170) evaluated for the type and prevalence of adverse health outcomes (AHOs). At median time from chemotherapy of 4.3 yr, the median number of AHOs in both the EPX4 and BEPX3 groups was two, with 34.3% and 35.1% of survivors, respectively, reporting three or more AHOs. While the most common AHOs including tinnitus and hearing impairment were similar between the groups, there were significant differences in the AHO type and incidence between the EPX4 and BEPX3 groups for Reynaud’s phenomenon (11.6% vs 21.4%; p < 0.01), peripheral neuropathy (29.2% vs 21.4%; p = 0.02), and obesity (25.5% vs 33%; p = 0.04). Increasing age and current smoking were associated with higher AHO rates, while exercise provided a protective effect.